FightMND Grant to Fund Phase 2 Study of Investigational Therapy for ALS

FightMND Grant to Fund Phase 2 Study of Investigational Therapy for ALS
0
(0)

Continuing its support for a potential therapy for amyotrophic lateral sclerosis (ALS), Australia-based organization FightMND has granted about $700,000 to biopharmaceutical company Collaborative Medicinal Development.

The money will fund a randomized, double-blind, placebo-controlled study of CuATSM, one of CMD’s lead investigational therapies. According to a news release, the Phase 2 study will begin later this year. Research details will soon be available at clinicaltrials.gov. The overall goal is to gain U.S. Food and Drug Administration (FDA) approval for the therapy.

“FightMND’s support for CMD to perform a Phase 2 study of CuATSM is consistent with our goals,”  said Rebecca Sheean, PhD, research manager for FightMND. “We are excited that our support for CMD has allowed CuATSM to advance toward the next phase of clinical testing.”

Established in 2014 to find treatments and a cure for motor neuron disease (MND), the nonprofit FightMND backed the medication’s Phase 1 trial three years ago.

Discuss the latest research in the ALS News Today forums!

The three-part trial (NCT02870634) showed that the once-daily oral medication may slow disease progression and improve patients’ respiratory and cognitive function. Studied in patients with sporadic and familial ALS, the investigation identified a Phase 2 recommended dose, examined CuATSM’s pharmacokinetic properties, confirmed treatment tolerability, and assessed the medication’s efficacy.

Data showed that after 24 weeks of CuATSM treatment at the recommended Phase 2 dose, ALS progression slowed markedly in those with sporadic ALS. Results also showed enhanced respiratory and cognitive ability. This is in line with preclinical studies in mouse models of ALS, which demonstrated that CuATSM performed dose-dependently when administered to animals.

The therapy is a small artificial molecule that can transport copper to cells containing damaged mitochondria, the cellular compartments that produce energy. Damaged mitochondria are widely considered a hallmark for ALS and other neurodegenerative diseases.

It is estimated that at least 30,000 people in the United States and 450,000 worldwide are living with ALS.

CMD, with bases in the United States and Australia, develops innovative therapies for neurodegenerative diseases.

 

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • Project ALS partnership
  • brain changes, ALS
  • EnClear Therapies receives key financing

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?